In addition to these molecular mechanism-based rationale for the limited success of IGF-1R therapeutics, trial design also played a role
However, it is crucial to understand that BPC-157 is not approved for human use by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, the European Medicines Agency (EMA), or the US Food and Drug Administration (FDA)
While 5-amino-1mq itself is not a stimulant, the enhanced energy production it supports could amplify stimulant effects
Ultimately, we reviewed 17 studies involving a total of 629 patients [39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55]